Oxford Nanopore Technologies (ONT · LSE)

ONT is rapidly growing in clinical genomics, with large-scale contracts supporting long-term revenue expansion.

Oxford Nanopore is the only company globally producing handheld, portable sequencing devices for real-time, in-field DNA/RNA analysis, —that sets it apart in next-generation genomic analysis.

ONT devices are deployed across multiple sectors spanning healthcare, agriculture, environmental science, and academic research, enhancing ONT’s market resilience and expanding its TAM.

Illumina and PacBio remain formidable competitors, leveraging existing market share and technology advancements.

ONT has yet to achieve consistent profitability, with high R&D and expansion costs potentially delaying EBITDA breakeven.

The transition from research to clinical applications presents regulatory and adoption challenges that may slow market penetration.